Support The Moscow Times!

Pharmstandard Sales Up

Despite regulatory tightening, drugmaker Pharmstandard posted a 14.7 percent year-on-year rise in second-quarter sales Thursday, reversing a 33 percent decline the previous quarter.

Pharmstandard's revenue amounted to 8 billion rubles ($244.16 million) in the April-through-June period, against 6.98 billion in the same period last year, the company said.

The growth comes despite a change in regulation of sales of codeine-containing medication, which led to a 54 percent drop in revenue from such products compared with the year earlier. The Russian government banned nonprescription sales of pain relievers containing codeine. First-half sales were still down 13.3 percent from a year ago to 16.2 billion rubles, mainly due to weaker sales of anti-flu drugs in the first quarter.

(Reuters)

Read more

Independent journalism isn’t dead. You can help keep it alive.

As the only remaining independent, English-language news source reporting from Russia, The Moscow Times plays a critical role in connecting Russia to the world.

Editorial decisions are made entirely by journalists in our newsroom, who adhere to the highest ethical standards. We fearlessly cover issues that are often considered off-limits or taboo in Russia, from domestic violence and LGBT issues to the climate crisis and a secretive nuclear blast that exposed unknowing doctors to radiation.

Please consider making a one-time donation — or better still a recurring donation — to The Moscow Times to help us continue producing vital, high-quality journalism about the world's largest country.